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ABSTRACT
The present prospective follow-up study was designed to identify
whether clinical, endocrine, or ultrasound characteristics assessed by
standardized initial screening of normogonadotropic oligo/amenor-
rheic infertile patients could predict conception in 160 women who
reached ovulation after clomiphene citrate (CC) medication. Addi-
tional inclusion criteria were total motile sperm count of the partner
above 1 million and a negative history for any tubal disease. Daily CC
doses of 50 mg (increasing up to 150 mg in case of absent ovarian
response) from cycle days 3–7 were used. First conception (defined as
a positive urinary pregnancy test) was the end point for this study. A
cumulative conception rate of 73% was reached within 9 CC-induced
ovulatory cycles. Patients who did conceive presented more frequently
with lower age (P , 0.0001) and amenorrhea (P , 0.05) upon initial
screening. In a univariate analysis, patients with elevated initial
serum LH concentrations (.7.0 IU/L) had a higher probability of
conceiving (P , 0.01). In a multivariate analysis, age and cycle history
(oligomenorrhea vs. amenorrhea) were identified as the only signif-
icant parameters for prediction of conception.
These observations suggest that there is more to be gained from CC
ovulation induction in younger women presenting with profound oli-
gomenorrhea or amenorrhea. Screening characteristics involved in
the prediction of ovulation after CC medication in normogonadotropic
oligo/amenorrheic patients (body weight and hyperandrogenemia, as
shown previously) are distinctly different from predictors of concep-
tion in ovulatory CC patients (age and the severity of cycle abnor-
mality). This disparity suggests that the FSH threshold (magnitude
of FSH required for stimulation of ongoing follicle growth and ovu-
lation) and oocyte quality (chances for conception in ovulatory cycles)
may be differentially regulated. (J Clin Endocrinol Metab 84: 1617–
1622, 1999)
THE SYNTHETIC antiestrogen clomiphene citrate (CC)represents an easy to use, convenient, inexpensive, and
safe first choice medication in normogonadotropic oligo/
amenorrheic infertility (WHO group 2) (1). Life-table anal-
ysis of pregnancy rates after CC medication and prediction
of treatment outcome have been the subject of extensive
investigation (2–10). Cumulative pregnancy rates after CC
treatment between 37–97% have been reported (3, 4, 6). A
positive correlation was established between body weight
and the CC dose required to induce ovulation (5, 10). More-
over, recent studies have indicated that body mass index
(BMI) is significantly higher in nonresponders (7, 10). Lim-
ited information is available, however, concerning the pre-
dictive value of initial screening characteristics for treatment
outcome (11), and previous investigators were unable to
identify predictors for conception after CC induction of ovu-
lation (6, 8, 10). All the above-mentioned studies focused on
the prediction of treatment outcome in the entire group of
infertile patients who started with CC medication. In con-
trast, we focused separately on the prediction of ovulation
after CC administration (12) and the prediction of conception
in ovulatory CC-treated women. This approach seems more
appropriate, because statistical bias due to selective drop out
from the study for reasons of persistent anovulation despite
increasing doses of CC medication is eliminated.
Our group could recently establish that obese hyperan-
drogenic amenorrheic patients are more likely to be resistant
to CC medication (12). We now report on initial clinical,
endocrine, and sonographic screening characteristics of nor-
mogonadotropic oligomenorrheic or amenorrheic infertile
women achieving ovulatory cycles after CC medication in an
attempt to identify factors predicting chances for conception
in these patients. The separate focus on the prediction of
conception and ovulation after CC treatment may allow dif-
ferentiation among factors affecting oocyte quality indepen-
dently from follicle development.
Subjects and Methods
Subjects and study protocol
Between February 1993 and December 1997, 160 couples presenting
with oligomenorrhea (bleeding intervals between 35 days and 6 months)
or amenorrhea (bleeding interval .6 months) and infertility attending
our unit were included in the present study. Additional inclusion criteria
were 1) serum FSH levels within normal limits (1–10 IU/L) (1, 13, 14)
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and normal serum PRL and TSH levels, 2) spontaneous menses or
positive bleeding response to progestagen withdrawal, 3) ovulatory
cycles after CC induction of ovulation, 4) BMI (weight divided by height
squared) greater than 18, 5) age between 19–40 yr, 6) a total motile sperm
count [TMC 5 ejaculate volume (milliliters) 3 sperm concentration
(106/mL) 3 percentage of progressive motile sperm] of the partner
above 1 million (15), 7) negative history for any tubal pathology, and 8)
no indication for intrauterine insemination. Study approval was ob-
tained from the human subject committee of the Dijkzigt Hospital/
Erasmus University, and informed consent was obtained from all sub-
jects included. A standardized clinical, endocrine, and sonographic
screening took place before initiation of induction of ovulation with CC
medication.
Ovulation after CC treatment was assessed by midluteal serum pro-
gesterone (P) levels above 25 nmol/L, combined with transvaginal sono-
graphic monitoring of follicle growth until visualization of a preovu-
latory follicle (mean diameter, .18 mm) and subsequent disappearance
or biphasic basal body temperature charts, as described previously (12).
Clomiphene citrate was administered at a daily dose of 50 mg (increased
to 100 and 150 mg in subsequent cycles in the case of absent ovarian
response) from cycle days 3–7 after initiation of spontaneous or pro-
gestin-induced withdrawal bleeding. Conception was defined as a pos-
itive urinary pregnancy test (Clearview, hCG II, Unipath Ltd., Bedford,
UK) more than 3 days after the expected menses, and ongoing pregnancy
was defined as sonographic assessment of an intrauterine gestational sac
with positive heart beat.
History and clinical screening included assessment of duration of in-
fertility, whether infertility was primary or secondary, cycle history, pre-
vious medication and/or surgery, and BMI. Endocrine screening included
serum assays of FSH, LH, estradiol (E2), testosterone (T), androstenedione
(AD), sex hormone-binding globulin (SHBG), and P. Fasting venous blood
samples were taken on a random day between 0800–1000 h, as indicated
previously (12). Blood samples were centrifuged within 2 h after with-
drawal and were stored at 220 C until assayed. Serum LH and FSH levels
were measured by immunofluorometric assay (Amerlite, Ortho-Clinical
Diagnostics, Amersham, Aylesbury, UK), as described previously (14). P
levels were measured by RIA, as described previously (16). Serum E2, T,
AD, and SHBG levels were estimated using RIA kits provided by Diag-
nostic Products (Los Angeles, CA), as described previously (17). Intra- and
interassay coefficients of variation were less than 3% and 8% for FSH, less
than 5% and 15% for LH, less than 16% and 17% for P, less than 5% and
7% for E2, less than 3% and 5% for T, less than 8% and 11% for AD, and
less than 4% and 5% for SHBG, respectively. Transvaginal pelvic ultrasound
(model EUB-415, Hitachi Medical Corp., Tokyo, Japan) was performed by
a single observer (B.I.) and included the assessment of ovarian stroma
amount and echogenicity (arbitrarily classified from one to three per ovary),
ovarian volume (milliliters), and total number of follicles (both ovaries), as
described previously (13, 18). Semen analyses were performed according to
WHO guidelines (1992) and comprised ejaculate volume (milliliters), num-
ber of spermatozoa per mL (106 spermatozoa/mL), percentage of progres-
sive motile spermatozoa, and percentage of normal forms (19).
Data analysis
A P value of 0.05 was chosen as the threshold level for statistical
significance. Cox regression has been used for life-table analysis of
conception rates during CC treatment (20). The number of ovulatory CC
treatment cycles was the time variable for multivariate analyses. Cen-
soring was defined as definitive discontinuation of CC therapy without
conception or end of follow-up (February 1998). To analyze the effect of
the severity of cycle abnormality on chances of conceiving after CC
treatment, we arbitrarily divided the cycle histories of the patients into
four categories; 5–6 weeks (n 5 56), 6–9 weeks (n 5 50), 9–26 weeks (n 5
25), and greater than 26 weeks (i.e. amenorrhea) (n 5 29). The univariate
relation was assessed between the variables listed in Table 1 and the time
interval between the first ovulation after CC medication and conception
using the Kaplan-Meier method (21) for categorical and the Cox regres-
sion (20) for continuous variables. The log-rank test has been used to
denote statistical significance in life-table analyses. The multivariate
analysis was performed with the method of forward stepwise selection
to gain a better insight into the interdependence between initial screen-
ing parameters. This method can explain why a variable that was sig-
nificantly different in univariate analysis was not selected in the final
model. The prognostic impact of variables was expressed as a fecund-
ability ratio, which is equivalent to the hazard ratio in survival analysis.
For instance, a fecundability ratio of 0.9 for an unfavorable group means
that the conception rate per ovulatory CC treatment cycle is 10% lower
compared to that in the favorable group. In some couples (n 5 25), no
sperm analysis was performed because of the short time interval be-
tween initiation of CC medication and conception. A statistical impu-
tation technique has been applied using multiple conditional mean
imputation to fill in these missing sperm parameters (22). The value of
semen parameters was estimated using the time until conception and
patient characteristics related to sperm parameters in the nonmissing
group. Data were analyzed using the commercially available software
package SPSS, Inc. (Chicago, IL).
Results
A total of 82 women (51% of the ovulatory group) conceived,
and 73 (46%) reached an ongoing pregnancy from the total of
160 patients fulfilling the in/exclusion criteria. Sixty-nine were
singleton and 4 were twin pregnancies (data not shown). Initial
screening parameters of 9 patients who had a miscarriage after
CC (11% of overall CC conceptions) were not different from
those of the remaining 73 patients who reached an ongoing
pregnancy (data not shown). One woman who conceived (twin
pregnancy) during her first CC treatment cycle was frequently
monitored on an out-patient basis due to abdominal discomfort
FIG. 1. Life-table analysis of CCR in 160 normogonadotropic oligoa-
menorrheic infertile patients who ovulated after CC medication. CCR
(including absolute number of patients at risk and number of events
(conceptions)) are presented for the total study group (upper panel;
vertical lines represent 95% confidence intervals) and separately for
women who reached ovulatory CC cycles with 50, 100, or 150 mg daily
for 5 subsequent days (lower panel). N represents the initial number
of patients at risk per dose group. P 5 log-rank test P value.
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and enlarged ovaries. There was no case of severe ovarian
hyperstimulation syndrome.
The life-table analysis of cumulative conception rates (CCR)
of patients who ovulated after CC are indicated in Fig. 1 for the
total group, and separately for different dose groups. A cumu-
lative conception rate of 47% was reached within three cycles
from first ovulation, and a CCR of 73% was reached within nine
CC-induced ovulatory cycles. Patients using daily doses of 50,
100, and 150 mg CC reached cumulative conception rates of
57%, 66%, and 38% within 5 ovulatory cycles, respectively
(Plog rank 5 0.25; Fig. 1). At higher doses, chances for conception
and ongoing pregnancy are not statistically significantly re-
duced, although absolute CCR (n 5 18) were low in the 150-mg
CC group. The overall mean duration of follow-up was 4 6 3
months and 3.2 6 2.6 ovulatory CC cycles. Initial screening
characteristics of the overall group of patients who ovulated
after CC and separately for those women who conceived
(n 5 82) vs. those who did not (n 5 78) are depicted in Table
1. Age, the severity of cycle abnormality (oligomenorrhea vs.
amenorrhea), and cycle duration, arbitrarily classified in four
categories (see also Materials and Methods), were significantly
different in univariate analysis. Age (cut-off of 30 yr), cycle
history (oligomenorrhea vs. amenorrhea), and initial serum LH
level (cut-off level of 7.0 IU/L) in univariate analyses for CCR
are depicted in Fig. 2. The percentages of ongoing pregnancies
per conception for patients with elevated (initial serum LH level
$7.0 IU/L) or normal initial serum LH levels were 84.8% and
94.4%, respectively (P value for difference in proportion ongo-
ing pregnancies 5 0.16, and 95% confidence interval for
difference 5 23% to 23%). The cut-off value for normal (i.e. 7.0
IU/L) was chosen on the basis of a previous study from our
group in normoovulatory controls (mean 6 1 sd) (23).
A total number of 159 patients had complete data on the
variables used in the multivariate analyses. Univariate anal-
ysis and forward stepwise multivariate analyses of all initial
parameters for the prediction of chances to conceive in ovu-
latory patients treated with CC are depicted in Table 2. Dur-
ing the stepwise multivariate analysis for the prediction of
chances to conceive, age, and cycle history (amenorrhea vs.
oligomenorrhea) entered into the model (steps 1 and 2, re-
spectively). The multivariate-adjusted fecundability ratio for
age was 0.90 (95% confidence interval, 0.85–0.95), and that
for amenorrhea was 0.54 (95% confidence interval,
0.32–0.93).
Discussion
The present prospective follow up study was designed to
evaluate whether initial screening characteristics of 160 nor-
mogonadotropic oligo/amenorrheic infertile women could
predict conception during ovulatory CC-induced cycles. Al-
though CC medication has been the focus of prevalent re-
search, limited information is available regarding the pre-
diction of conception as treatment outcome (11). Reported
cumulative pregnancy rates vary between 37–97%. Most
studies, however, suffer from methodological difficulties
and different inclusion/exclusion criteria. For the first time,
our group has focused on ovulation and conception in sep-
TABLE 1. Initial clinical, endocrine, and ultrasound screening characteristics and sperm parameters of partners (median and range) of
160 normogonadotropic oligomenorrheic or amenorrheic infertile women who ovulated after CC induction of ovulation (overall group) and
did or did not (CC failure) conceive
Screening parameters Overall group(n 5 160)
Conceived
(n 5 82; 51%)
CC failure
(n 5 78; 49%) P value
a
Clinical
Age (yr) 28 6 4 27 6 4 29 6 4 0.0001
Infertility duration (yr) 1.9 6 2.3 1.6 6 1.4 2.2 6 2.9 0.23
Primary infertility (n) 116 62 54 0.40
Amenorrhea (n) 29 18 (62) 11 (38) 0.04
Bleeding interval in 4 categories 0.05
5–6 weeks, n (%) 56 (35) 22 34
6–9 weeks, n (%) 50 (31) 29 21
9–26 weeks, n (%) 25 (16) 13 12
.26 weeks, n (%) 29 (18) 18 11
BMI (kg/m2) 26 6 6 26 6 6 25 6 6 0.46
Endocrine
LH (IU/L) 7.6 6 4.2 8.2 6 4.3 6.9 6 4.0 0.11
T (nmol/L) 2.3 6 1.0 2.3 6 1.0 2.3 6 1.0 0.85
AD (nmol/L) 15.0 6 6.9 15.8 6 7.9 14.0 6 5.7 0.16
FAIc 5.4 6 3.9 5.5 6 4.1 5.1 6 3.7 0.20
SHBG (nmol/L) 56 6 31 54 6 27 58 6 35 0.24
E2 (pmol/L) 259 6 175 229 6 145 290 6 198 0.10
Ultrasound
Mean ovarian vol (mL) 9.3 6 3.7 9.2 6 3.7 9.4 6 3.7 0.97
Mean follicle no. 12 6 5 12 6 5 12 6 5 0.48
Total stroma scored 3.2 6 1.1 3.1 6 1.1 3.3 6 1.2 0.66
Total motile sperm count (TMC) 73 (1.1–492) 75 (1.5–303) 72 (1.1–492) 0.32e
% Normal morphology 24 (1–50) 20 (1–50) 25 (1–50) 0.34e
Values are the mean 6 SD. Underlined values are statistically significant.
a Comparison of CC-conceived vs. CC failure (univariate Cox regression).
b Chances to conceive differ among four categories of bleeding interval.
c FAI 5 T 3 100/SHBG.
d Arbitrarily defined as one to three per ovary (both ovaries added).
e Computed with multiple imputation of missing values.
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arate steps, taking into account that a significant proportion
(23%) of patients who remain anovulatory after CC medi-
cation (12) have no chance of conception. Inclusion of these
patients in a study focusing on conception causes statistical
bias. This separate focus may offer a better insight into the
potential predictive power of initial screening characteristics
in a heterogeneous group of normogonadotropic oligo/am-
enorrheic infertile women (WHO class 2) for CC-induced
follicle growth and ovulation, separately from conception.
In the present study, CCR of 63% within six cycles and 73%
within nine ovulatory CC-induced cycles have been reached.
Two thirds of patients who conceived reached this end point
within the first three ovulatory CC treatment cycles. This is
in agreement with previous reports in the literature regard-
ing CC (3, 24, 25) and is similar to spontaneous conception
chances in normoovulatory women (26). This is also com-
parable to conception rates reported for exogenous gonad-
otropin induction of ovulation (27–29) in anovulatory infer-
tile patients. These observations strongly suggest that the
overall detrimental effects of CC on cervical mucus produc-
tion or endometrial receptivity and subsequent implantation
are limited with daily CC doses up to 150 mg. Although the
CCR seems to be lower in the high dose CC group, this
finding was not statistically significant. It should be noted
that the sample size of this group was limited, so actual
differences cannot be excluded.
Previous studies were unable to identify predictors for
conception in CC induction of ovulation in normogonado-
tropic infertile women (6, 8, 10). In the present study, age and
cycle history (amenorrhea or oligomenorrhea) were signifi-
cantly different comparing patients who conceived vs. those
who did not during CC-induced ovulatory cycles. Multivar-
iate analyses revealed a final model including age and cycle
history. The predictive power of age was highest. The area
under the receiver operating characteristics curve of the final
model including these two factors reached 0.68 (data not
shown), which is substantially lower than that in the previ-
ous model predicting ovulation after CC (0.82) (12). For rea-
sons of clarity, the forward stepwise approach was chosen.
Backward stepwise analysis was also applied, resulting in
the same final model (data not shown). Young patients have
a higher probability to conceive during CC-induced ovula-
tory cycles. The fecundability rate of the patient decreases by
approximately 10%/yr. This is in agreement with reports
that indicate that age is an important factor for the prediction
of chances for spontaneous conception in untreated nor-
FIG. 2. Univariate analysis of CCR in 160 normogonadotropic oli-
goamenorrheic infertile patients per ovulatory CC cycle. Initial
screening parameters shown are 1) patient’s age (cut-off level at 30
yr; upper panel), 2) cycle history (oligomenorrhea vs. amenorrhea;
middle panel), and 3) initial serum LH concentrations (cut-off level of
7.0 IU/L; lower panel). n represents the initial number of patients at
risk. P 5 log-rank test P value.
TABLE 2. Forward stepwise multivariate analyses of initial
screening characteristics for the prediction of chances to conceive
in 159 normogonadotropic oligo-amenorrheic infertile women who
ovulated after CC induction of ovulation
Analyses steps Univariate:0a
Multivariate
1 2
Screening parameters
Clinical
Age (yr) 0.0001 In model In model
Amenorrhea (n 5 29) 0.04 0.02 In model
Bleeding interval (in four
categories)
0.05 0.06 0.30
Endocrine
LH (IU/L) 0.11 0.36 0.26
FAIb 0.20 0.56 0.38
AD (nmol/L) 0.16 0.38 0.15
E2 (pmol/L) 0.10 0.26 0.39
Numbers are P values for inclusion in the model. Underlined num-
bers are significant at P , 0.05.
a Only screening parameters with a univariate P # 0.2 (see Table
1) are shown. In the univariate analysis (step 0), three variables reach
statistical significance (underlined). In step 1 of the multivariate
analysis the variable with the highest prognostic information (age) is
selected. After the first step, amenorrhea still reaches statistical
significance and, therefore, is selected in the second step. Thereafter,
no additional variable is statistically significant anymore, indicating
that the model cannot be improved by selecting a subsequent param-
eter.
b FAI 5 T 3 100/SHBG.
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moovulatory subfertile patients (30–32). Similar findings
have been reported for the prediction of chances to conceive
after exogenous gonadotropin induction of ovulation (27)
and in vitro fertilization treatment (33).
Amenorrheic patients exhibit a 2-fold higher probability to
conceive after ovulatory CC cycles compared to oligomenor-
rheic patients. Patients with longer bleeding intervals also ex-
hibit higher conception chances. We have been unable to find
similar reports in the literature regarding induction of ovula-
tion. The most likely explanation seems to be the following.
Patients with amenorrhea have an extremely low probability to
conceive without intervention due to anovulation before seek-
ing help by a physician. Presumably, the major subfertility
factor in these patients is chronic anovulation, which can be
resolved temporarily by the use of CC medication. These pa-
tients are more likely to be at low risk for any other subfertility
factor, such as tubal or sperm dysfunction. Some oligomenor-
rheic patients may have spontaneous ovulations (34), and some
of these women may never seek medical intervention because
of spontaneous pregnancies. Their benefit from ovulation in-
duction is an increased chance for conception due to an in-
creased number of ovulations with a fixed interval in a given
period of time. Similar observations were made for pregnancy
chances after artificial insemination with donor sperm in rela-
tion to the sperm quality of the partner. Donor insemination
outcome is significantly better in cases with very poor sperm
quality (35). One should consider that amenorrheic patients also
have a higher probability to remain anovulatory after CC, as
demonstrated previously (12). In contrast, regular ovulatory
cycles are easier to induce with CC in oligomenorrheic patients,
but there is less chance of pregnancy.
In the present study, patients with elevated initial serum
LH levels have a significantly higher probability to conceive
once ovulatory cycles have been achieved by CC. A recent
study also indicated higher initial LH levels in patients who
conceived after CC medication (10). In contrast, a poor treat-
ment outcome has been observed in patients with high LH
levels during the follicular phase of CC-induced cycles (8). It
should be realized that we report on initial LH levels before
initiation of CC medication, rather than during CC-induced
cycles. Indeed, elevated LH levels may normalize only dur-
ing CC-induced ovulatory cycles (36). These observations are
in sharp contrast with reports regarding patients with ele-
vated LH who perform poorly during gonadotropin induc-
tion of ovulation (28) or in vitro fertilization (37). We previ-
ously showed that initial LH concentrations did not predict
patients who would remain anovulatory after CC medication
(12). The present observation seems to dispute previous be-
liefs concerning the detrimental effects of elevated LH levels
on oocyte maturation and capacity for fertilization. In addi-
tion, we did not observe a higher spontaneous abortion rate
in patients with high LH levels who conceived after CC
medication. This finding is also in contrast with previous
reports on the effects of high LH concentrations on chances
for spontaneous abortion after exogenous gonadotropins (38,
39). The predictive power of the initial LH level is poor in case
age enters in the final model, which may be due to a corre-
lation of initial LH with age (data not shown). The mecha-
nism of action of CC is not fully elucidated, and the role of
LH in the pathogenesis of ovarian abnormalities remains
open for speculation. As an example, female siblings of male
patients described with an activating mutation of the LH
receptor (so-called familial male testotoxicosis) seem to be
without a clear phenotype (40).
Total motile sperm count is not a predictor in univariate
or multivariate analyses of prediction of conception in the
present study population. This is in agreement with the ob-
servation that a large overlap exists between semen charac-
teristics of males from fertile vs. subfertile couples (15). More-
over, it can be speculated that couples with better sperm
parameters have already conceived spontaneously before
seeking medical intervention.
In summary, it can be concluded that body weight and
hyperandrogenemia are the predominant predictors for
ovulation after CC treatment, whereas age and cycle his-
tory dictate pregnancy chances in ovulatory women. This
stresses for the first time the important concept that follicle
growth and oocyte quality (and subsequent capacity to be
fertilized in vivo) are differentially regulated during in-
duction of ovulation, confirming observations during in
vitro fertilization.
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